A5101603119- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Chemotherapy-related skin toxicity
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Angiogenesis and VEGF in Cancer
- Lung Cancer Research Studies
- Hair Growth and Disorders
- Breast Lesions and Carcinomas
- Cancer Diagnosis and Treatment
- Cancer Risks and Factors
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Colorectal Cancer Surgical Treatments
- Cancer-related Molecular Pathways
University of Catania
2022-2024
Ospedale A. Perrino
2015-2024
Institute of Oncology Research
2019-2023
Università della Svizzera italiana
2020-2023
Lund University
2020
Ente Ospedaliero Cantonale
2020
European Institute of Oncology
2004-2019
GTx (United States)
2019
University of Basel
2019
University Hospital of Basel
2019
This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib patients human epidermal growth factor receptor 2 (HER2) -positive, stage to IIIA operable breast cancer. The primary aim was estimate the percentage pathologic complete response (pCR; no invasive tumor and axillary nodes).In three arms, chemotherapy consisted weekly paclitaxel (80 mg/m(2)) for 12 weeks followed by...
Abstract BACKGROUND Aging remains one of the single greatest risk factors for development new breast carcinoma. The aim study was to evaluate relation between biologic features at first diagnosis carcinoma and treatment choice postmenopausal women ≥ 50 years optimize in elderly. METHODS sample included 2999 consecutive patients referred surgery European Institute Oncology (Milan, Italy) from April 1997 February 2002. were grouped according age: young (YPM; 50–64 years, n = 2052), older (OPM;...
HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We therefore tested the activity combination Trastuzumab with metronomic, low dose chemotherapy cyclophosphamide (CTX) and methotrexate (MTX) metastatic cancer (MBC). Between April 2002 June 2005, twenty-two patients presence or amplification HER2-/neu, all pre-treated trastuzumab plus other cytotoxics, were treated (6 mg/kg every three weeks) metronomic (MTX 2.5 mg, bid on Day 1 4 week) CTX (50 mg daily) (CM)....
Breast cancer is the most frequent tumor and leading cause of deaths in women. In recent years, lactate metabolism and, particular, its receptor GPR81 have been shown to play a vital role biology. upregulated breast promotes growth by cell-derived lactate. Therefore, search for possible crosstalk involvement new molecules capable generating this pathology always continuous development. study, relationship between IGFBP6 protein oxidative stress human cell line MDA-MB-231 was studied. Cells...
In spite of the effectiveness endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors as first-line treatment for estrogen receptor (ER)-positive, erb-b2 tyrosine 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), patients eventually develop resistance, and most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral with intravenous (IV)
The clinical efficacy and antiangiogenic effect of low-dose, metronomic administration cyclophosphamide (CTX) methotrexate (MTX) (CM) have been demonstrated. authors report results long-term follow-up for patients with metastatic breast carcinoma who obtained prolonged benefit CM. Prospectively collected data from two successive trials were evaluated. From July 1997 to October 2003, treated low-dose oral chemotherapy (MTX 2.5 mg, twice daily on day 1 2 or 4, CTX 50 mg daily). Patients...
Aim Pathological predictive factors are the most important markers when selecting early breast cancer adjuvant therapy. In randomized clinical trials variability in pathology report after central review is noteworthy. We evaluated discordance rate (DR) and inter-rater agreement between local histopathological implication on treatment decision. Methods A retrospective analysis was conducted a series of consecutive tumors diagnosed by pathologists subsequently reviewed at Pathology Division...
Tobacco smoking remains the leading cause of preventable death globally. This study examines effects cigarette smoke (1R6F) and heated tobacco product (HTP) aerosols on microglial activation, cell proliferation, proteomic changes under hypox-ia-reoxygenation (H/R) conditions, focusing nicotine's role in oxidative stress, in-flammation, Nrf2 pathway activation. H/R conditions significantly activated micro-glia, consistent with prior evidence linking hypoxic stress to...
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of lipids within hepatocytes, which compromises functionality following mitochondrial dysfunction and increased production reactive oxygen species (ROS). Lipoic acid one prosthetic groups pyruvate dehydrogenase complex also known for its ability to confer protection from oxidative damage because antioxidant properties. In this study, we aimed investigate effects lipoic on lipotoxicity dynamics in an vitro model...